Amifostine in the management of radiation-induced and chemo-induced mucositis.
BACKGROUND
Mucositis is a significant complication of cancer therapy, with important clinical and economic implications. In June 2005, the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO) conducted an evidence-based update review of the literature on mucositis. The goal of this literature review is to update previously published guidelines for the management of mucositis.


RESULTS
This article reports the findings of the subgroup charged with reviewing the literature related to amifostine.
Bensadoun
Rene-Jean
RJ
Department of Radiation Oncology, Centre Antoine-Lacassagne, 33 Av. de Valombrose, 06189, Nice, Cedex 2, France. rene-jean.bensadoun@nice.fnclcc.fr
Schubert
Mark M
MM
Lalla
Rajesh V
RV
Keefe
Dorothy
D
D004999:Amifostine / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects; D003131:Combined Modality Therapy; D004941:Esophagitis / Q000188:drug therapy / Q000209:etiology; D019317:Evidence-Based Medicine; D005767:Gastrointestinal Diseases / Q000188:drug therapy* / Q000209:etiology; D006258:Head and Neck Neoplasms / Q000628:therapy; D019337:Hematologic Neoplasms / Q000628:therapy; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy; D052016:Mucositis / Q000188:drug therapy* / Q000209:etiology; D009369:Neoplasms / Q000150:complications / Q000628:therapy*; D010386:Pelvic Neoplasms / Q000628:therapy; D017410:Practice Guidelines as Topic; D011349:Proctitis / Q000188:drug therapy / Q000209:etiology; D011837:Radiation-Protective Agents / Q000627:therapeutic use*; D011878:Radiotherapy / Q000009:adverse effects; D012107:Research Design; D013280:Stomatitis / Q000188:drug therapy* / Q000209:etiology; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D011837:Radiation-Protective Agents; D004999:Amifostine